|Trade names||Doribax, Finibax|
|Main uses||Complicated intra-abdominal infections, urinary tract infections, or pneumonia|
|Side effects||Infusion site pain, diarrhea, nausea, rash, itchiness, headache|
|Chemical and physical data|
|Molar mass||420.50 g·mol−1|
|3D model (JSmol)|
Doripenem, sold under the brand names Doribax among others, is an antibiotic used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is generally effective against Pseudomonas. It is given by injection into a vein.
Common side effects include infusion site pain, diarrhea, nausea, rash, itchiness, and headache. Other side effects may include anaphylaxis, seizures, and liver problems. While there is no evidence of harm in pregnancy, such use has not been well studied. It is a beta-lactam in the carbapenem class.
Doripenem was approved for medical use in the United States in 2007. While it was approved in Europe in 2008, it was subsequently withdrawn. In the United States 7 days of treatment used to cost about 680 USD. As of 2021; however, it is no longer commercially available.
The recommended dosage is 500 mg given intravenously every 8 hours for 5 to 14 days.
Potential avenues for the development of resistance to doripenem are: altered PBPs (penicillin-binding protein), reduced activity in the permeability of the outer membrane especially when accepting foreign toxic substances within the cell, and deactivation of the drug by hydrolyzing enzymes from the carbapenem. Beta-lactamases (such as penicillinases) formed by gram-positive and gram-negative bacteria can stabilize doripenem to hydrolysis. However, carbapenem-hydrolyzing beta-lactamases are an exception.
- Seizure risk: carbapenems in general have been reported to cause seizure activity in some people. In addition, those who already have a seizure disorder may be at risk for further seizures if they are using valproic acid to control their seizures; doripenem has been found to decrease serum concentrations of valproic acid.
- Infection related: use of doripenem can lead to clostridium difficile infection. It has also been noted to increase mortality in people who have ventilator-associated bacterial pneumonia, and is no longer recommended as a treatment for this condition.
Doripenem is a beta-lactam antibiotic agent belonging to the carbapenem group, with a broad spectrum of bacterial sensitivity including both gram-positive and gram-negative bacteria. In vivo, doripenem inhibits the synthesis of cell walls by attaching itself to penicillin-binding proteins, also known as PBPs. However it is not active against MRSA. It is stable against beta-lactamases including those with extended spectrum, but it is susceptible to the action of carbapenemases. Doripenem is also more active against Pseudomonas aeruginosa than other carbapenems.
The greater stability of doripenem in aqueous solution compared to earlier members of the carbapenem class allows it to be administered as an infusion over 4 hours or more, which may be advantageous in the treatment of certain difficult-to-treat infections. It may present a lower risk of inducing seizures than other carbapenems.
Doripenem appears as crystalline powder, with colour anywhere from a white to somewhat yellowish. Doripenem is moderately soluble in water, slightly soluble in methanol, and virtually insoluble in ethanol. Doripenem is also soluble in N,N-dimethylformamide. Doripenem's chemical configuration has 6 asymmetrical carbon atoms (6 stereocentres) and is most commonly supplied as one pure isomer. In terms of doripenem for injection, the crystallized powdered drug can form a monohydrate when mixed with water. However, doripenem has not been proven to possess polymorphism
On average, about 8.1% of plasma proteins attached to doripenem; it is separate from drug concentrations of plasma. Doripenem’s distribution volume is close to that of extracellular fluid volume in humans (18.2 L). When doripenem is essentially stable, the average volume of distribution is approximately 16.8 L. Within the few of the body’s fluids and tissues, Doripenem is filtered successfully as well as reaching concentration levels that are able to restrain from more vulnerable bacteria than what is required.
Doripenem is metabolized by the enzyme dehydropeptidase-I into an inactive ring-opened metabolite.
In young and healthy adults, the elimination half-life of doripenem considering the average plasma terminal is normally around 1 hour. The plasma clearance is about 15.9 L/hour and the average renal clearance is 10.3 L/hour. Research indicates doripenem is filtered by the glomerular capillary bed in Bowman’s capsule and the tubular secretions in the nephron.
Society and culture
Regulatory and marketing
It was launched by Shionogi Co. of Japan under the brand name in 2005 and is being marketed outside Japan by Johnson & Johnson. Doripenem was approved by the United States Food and Drug Administration on October 12, 2007, to be sold under the tradename Doribax. It is the fourth member of the carbapenem class to be approved in the United States.
- "Doripenem". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 27 December 2021.
- "Doripenem Monograph for Professionals". Drugs.com. Archived from the original on 2 August 2019. Retrieved 27 December 2021.
- "Doripenem (Doribax) Use During Pregnancy". Drugs.com. Archived from the original on 23 November 2020. Retrieved 27 December 2021.
- "Doribax". Archived from the original on 26 October 2021. Retrieved 27 December 2021.
- "Doripenem Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 27 December 2021.
- "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 27 August 2021. Retrieved 27 December 2021.
- "Highlights of Prescribing Information: DORIBAX (doripenem for injection)" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 2018-11-01. Retrieved 2020-12-26.
- "Doripenem for Injection for the Treatment of Nosocomial Pneumonia" (PDF) (Press release). Johnson & Johnson. July 16, 2008. Archived (PDF) from the original on 2017-05-16. Retrieved 2010-05-19.
- Mazzei T (August 2010). "The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem". Journal of Chemotherapy. 22 (4): 219–25. doi:10.1179/joc.2010.22.4.219. PMID 20685624. S2CID 72019292.
- Greer ND (July 2008). "Doripenem (Doribax): the newest addition to the carbapenems". Proceedings. 21 (3): 337–41. doi:10.1080/08998280.2008.11928422. PMC 2446428. PMID 18628935.
- Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R (2009). "Overview of seizure-inducing potential of doripenem". Drug Safety. 32 (9): 709–16. doi:10.2165/00002018-200932090-00001. PMID 19670912. S2CID 25385572.
- "FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections" (Press release). U.S. Food and Drug Administration. October 17, 2007. Archived from the original on 2009-05-29. Retrieved 2007-10-25.
- Nishino Y, Kobayashi M, Shinno T, Izumi K, Yonezawa H, Masui Y, Takahira M (November 2003). "Practical large-scale synthesis of doripenem: A novel 1β-methylcarbapenem antibiotic". Organic Process Research & Development. 7 (6): 846–50. doi:10.1021/op034088n.
- "CHMP Assessment Report for Doribax" (PDF). European Medicines Agency. 2008. Archived (PDF) from the original on 2020-02-19. Retrieved 2020-12-26.
- Hagerman JK, Knechtel SA, Kiepser ME (December 2007). "Doripenem: A new extended-spectrum carbapenem antibiotic". Formulary. 42 (12): 676–688.